MAPT and early-onset autosomal dominant Alzheimer disease: These results suggest that GSPE could be a potential protective agent in the treatment of Alzheimer’s disease (AD), as AD is characterized by increased Aβ, hyperphosphorylation and tau protein aggregation [109].